cyclohexanol has been researched along with Multiple Sclerosis in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ahmed, Z; Baker, D; Croxford, JL; Cuzner, ML; Giovannoni, G; Hankey, DJ; Jackson, SJ; Ledent, C; Petzold, A; Pocock, JM; Pryce, G; Thompson, AJ | 1 |
Baker, D; Pryce, G | 1 |
2 other study(ies) available for cyclohexanol and Multiple Sclerosis
Article | Year |
---|---|
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis.
Topics: Animals; Aspartic Acid; Axons; Benzoxazines; Cannabinoids; Cyclohexanols; Dizocilpine Maleate; Encephalomyelitis, Autoimmune, Experimental; Excitatory Amino Acid Agonists; Gene Deletion; Humans; Mice; Mice, Transgenic; Monomeric GTP-Binding Proteins; Morpholines; Multiple Sclerosis; N-Methylaspartate; Naphthalenes; Nerve Degeneration; Nuclear Proteins; Receptors, Cannabinoid; Receptors, Drug; Receptors, N-Methyl-D-Aspartate; Retina; Saccharomyces cerevisiae Proteins; Spinal Cord; Uveitis | 2003 |
Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors.
Topics: Animals; Benzoxazines; Body Temperature; Cross Reactions; Cyclohexanols; Encephalomyelitis, Autoimmune, Experimental; Mice; Mice, Knockout; Morpholines; Multiple Sclerosis; Muscle Spasticity; Naphthalenes; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2 | 2007 |